4 citations
,
June 2024 in “British Journal of Dermatology”
This study found that treatment with EGFR inhibitors or mitogen-activated kinase inhibitors may compromise the immune privilege of human scalp hair follicles, suggesting new directions for managing drug-induced folliculitis.
3 citations
,
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology”
This research suggests that innate lymphoid cells type 1 (ILC1) may contribute to the development of alopecia areata, alongside CD8+ T cells, by disrupting hair follicle immune privilege and promoting features of the disease.
April 2017 in “Journal of Investigative Dermatology”
This study found that miR-486 and miR-451 levels were reduced in alopecia areata-affected skin, and delivering their mimics to mice mitigated symptoms by reducing inflammation and immune activity.
47 citations
,
December 2011 in “Experimental Dermatology”
This study suggests that the neuropeptide CGRP may protect against, but not restore, IFNγ-induced collapse of hair follicle immune privilege in alopecia areata.
Scientists have grown natural-looking hair from stem cells, potentially revolutionizing hair growth treatments. Concerns include cost, DHT resistance, and the need for future procedures.
Deoxyribose sugar gel may stimulate hair regrowth similarly to minoxidil by enhancing blood supply and follicle activity. Human trials are necessary, and current products have mixed results.